Primary Care for Recent Immigrants (Kasten-Arias 4/2025)

A recording of this presentation is available HERE (check back for live link).

***

Many thanks to Dr. Cassandra Kasten-Arias, who gave our final Senior Resident presentation of the academic year. Don't worry, we still have a few more weeks of Grand Rounds before we take a summer break. Dr. Kasten-Arias gave an important and timely presentation on Primary Care in Recent Immigrants. 

The first part of her talk featured the medical indications for specific screening tests for refugees and/or recent immigrants; the second half focused on recent executive policy changes and what clinicians need to know to reassure patients about their rights and to respond to the presence of immigration officials in clinic and hospital spaces. I recommend watching!

For those of you who prefer notes:

Those of us who work in community health are aware of the immigrant populations we currently care for in our particular communities. As seen in the images below, the largest share of immigrants in the US are from Mexico, followed by India and China. In contrast, the largest number of refugees in the US currently are from China, Afghanistan and El Salvador. 



Whereas there are guidelines from the CDC for clinicians caring for refugees, most undocumented immigrants will present to our healthcare facilities having received little to no standardized health screening. 


Dr. Kasten-Arias encouraged us to refer to these guidelines-- found here -- when caring for all recent immigrants. 

When caring for recent immigrants, there are specific areas to pay attention to, including vaccination history, travel history, environmental exposure, infectious disease screening, mental health, and sexual health screening.

Vaccination 
  • Verify the validity of vaccine records (criteria for validity: name of vaccine, month and year of administration, recommended timeline)
  • Which vaccines are due or need revaccination
  • When records are missing, favor administration over serologic testing (risk of repeat is low)

Travel History
  • country of origin
  • countries along immigration journey
  • any other recent travel
Environmental Exposures
  • Lead screening recommended by CDC for all newly arrived refugees/immigrants
  • special attention to lead (>3.5ug/dl) due to high prevalence among refugees, who may have increased risk due to nutritional deficiencies of iron/calcium/zinc
  • special attention to young children, pregnant and breastfeeding patients
  • common lead sources in immigrants: car batteries (used to keep warm during journey), glazed pottery, industrial emissions, lead paint, herbal supplements, gasoline, candies (esp tamarind)




Infectious Disease Screening
  • HIV (age 13-64, AND children <13 if high risk and/or unknown maternal status)
  • TB -- 85% of US cases is reactivation of latent TB in immigrants-- screen with TST/IGRA for all children over 2 and TST for <2
  • Intestinal parasites: almost all immigrants, regardless of country of origin, are at risk for stronglyoides infection. Check O+P for anyone with unexplained eosinophilia on CBC
  • Viral Hepatitis
    • HBV, highest risk from specific geographic areas, including SE Asia, West Africa, some parts of Sub-Saharan Africa
      • CDC recommends screening ALL adults for HBV if not previously screening, children <18 if not completely vaccinated and no previous testing, all pregnant people regardless of previous vaccination
      • Offer HBV vaccine to unvaccinated
    • HCV screening for all adults, consider for unaccompanied minors and children w/risk factors

An excellent resource for refugees/recent immigrants is CareRef (from Minnesota): https://careref.web.health.state.mn.us/, which compiles CDC recommendations into an easy to use form and helps clinicians guide screening assessments. 



Mental health screening tool for refugees/newly arrived immigrants: https://www.cdc.gov/immigrant-refugee-health/hcp/domestic-guidance/mental-health.html

Sexual Health screening: 60% of women/girls experience sexual assault on journey to the border (Amnesty International 2010)
  • CDC recommends contraception counseling, STI screening, family planning services
  • pregnancy test for all refugees
  • inform patients of confidential services for teens (>12 in CA)
  • female genital cutting: https://www.cdc.gov/immigrant-refugee-health/hcp/domestic-guidance/sexual-and-reproductive-health.html

Screening Labs for initial visit:

Political Context and Advocacy Resources
We are all aware of the current political context with direct attacks by the federal administration on immigrant populations. In January 2025, the administration removed historical protections that protected immigration enforcement in hospitals, clinics, schools and places of worship.

 In March of 2025, The Physicians for Human Rights (PHR) released a document specifically for healthcare providers titled Health Care and US Immigration Enforcement: What Providers Need to Know


What can we do as healthcare providers?
  • Proactively reassure patients
  • Do not ask about immigration status unless required (we are NOT required in California)
    • in states where you are required, you can inform patients that while we are required to ask, they are not required to respond
  • Monitor and address rumors
  • Share Know Your Rights information
    • regardless of status, all patients have right to privacy, emergency care, and equal protection
  • Ensure institutional preparedness protections against immigration enforcement
    • right to remain silent (while immigration officials can enter any public space and question anyone, those being questioned have the right to remain silent and not respond to those questions)
    • plain view: officers can have access to anything in plain view BUT cannot move things to get information (e.g. keep health records out of sight)
    • warrants must be signed by a judge, have an individual's name on it, state the site at which it will served and accurate dates
    • we are permitted to document and/or video any encounter with immigration officials

Northbay Rapid Response Network: https://www.northbayop.org/nbrrn


Additional resources:



Practicing Changing OB Updates in 2024-25 (Watson, 4/23/2025)

 A recording of this presentation is available HERE.

***

Thanks to Dr. Hannah Watson, our interim Maternity Care Director at the Santa Rosa Family Medicine Residency, for an excellent talk on 2024-2025 OB Updates. She covered five studies recently published, which suggested some practice changes in the care of OB/Gyn patients. I love looking at recent literature to either reinforce our current practice or to update in real time what we do clinically. 

She also toured us through some beautiful wildflowers!


Here are my take home pearls:

1) VTE prophylaxis in patients after c-section (while hospitalized) may not change outcomes. 

In this retrospective cohort study of patients who received VTE ppx vs. those who didn't, 0.31% vs 0.08% (not statistically significant) developed VTE; 6.7% vs. 1.7% were readmitted, 3% vs 1% wound complications.

Bruno AM, Sandoval GJ, et al Postpartum pharmacologic thromboprophylaxis and complications in a US cohort. Am J Obstet Gynecol. 2024 Jul;231(1):128.e1-128.e11. doi: 10.1016/j.ajog.2023.11.013. Epub 2024 Feb 12. PMID: 38346912; PMCID: PMC11194157.

2) While antepartum betamethasone (for fetal lung maturity) has excellent evidence prior to 34 weeks EGS, in patients who deliver at 34-36 weeks, the positive impact of maternal steroids varies based on gestational age AND mode of delivery (LTCS vs. vaginal). 

In this secondary analysis of the 2017 Antenatal Later Preterm Steroids (ALPS) Trial, 7ounger gestational age and surgical delivery confer greater benefit of steroids. Of note, GDM patients were excluded from the ALPS trial.

Clapp MA, Li S, Cohen JL, Gyamfi-Bannerman C,  et al Betamethasone Exposure and Neonatal Respiratory Morbidity Among Late Preterm Births by Planned Mode of Delivery and Gestational Age. Obstet Gynecol. 2024 Dec 1;144(6):747-754. doi 10.1097/AOG.0000000000005756. Epub 2024 Oct 10. PMID: 39388700.

3) Pregnant patient with GDM may benefit with improved glucose control from split dosing their long acting (i.e. glargine) insulin when using over 20-30 units per day. Also injecting prandial insulin 20-30 minutes BEFORE eating improves glycemic control. 

Valent AM, Barbour LA. Insulin Management for Gestational and Type 2 Diabetes in Pregnancy. Obstet Gynecol. 2024 Nov 1;144(5):633-647. doi: 10.1097/AOG.0000000000005640. Epub 2024 Jun 13. PMID: 38870526.

4) Concurrent partner treatment (oral metronidazole and topical clindamycin) for patients with bacterial vaginosis (BV) reduces risk of recurrence of BV by 50% at 12 weeks. 

Recurrence rates of BV were still high: 63% at 12 weeks in the control group (no partner treatment) and 35% in the partner treatment group.

https://www.nejm.org/doi/full/10.1056/NEJMoa2405404

5) The Jada (aspiration system) demonstrates equivalent outcomes to the Bakri (balloon system) for post partum hemorrhage management.

Of note, Dr. Watson says that both she and patients generally prefer the Jada system, which generally stays in for one hour; whereas the Bakri requires traction for up to 12 hours. Evidence shows either system is better the sooner it is placed.

Shields, Laurence E. MD; Klein, Catherine MSN, RN et al Effectiveness of the Intrauterine Balloon Tamponade Compared With an Intrauterine, Vacuum-Induced, Hemorrhage-Control Device for Postpartum Hemorrhage. Obstetrics & Gynecology 145(1):p 65-71, January 2025. | DOI: 10.1097/AOG.0000000000005770


Options for Menstrual Suppression (Mak, 4/16/25)

 A recording of this presentation is available HERE.  

Thanks to Dr. Ray Mak for a good refresher on menstrual suppression. A reminder from Dr. Mak up front that there are varied reasons that people with a uterus prefer to suppress their menstruation -- from personal preference to medical indications, and we can and should know how to counsel them on how to safely do so.

Check out this table that outlines some of the reasons for menstrual suppression. Not included in the table are financial reasons (people spend $6000-$18,000 over their lifetime for menstrual products) or cancer risk reduction. 

Patient preference

 

Challenges with menstrual hygiene

Intellectual or developmental delay

Limited dexterity or mobility 

Gynecologic

Dysmenorrhea

Endometriosis-related pain and bleeding

Menorrhagia

PMS

Abnormal uterine bleeding

Work or social indications

Military deployment or space travel

Athletes

Camping or wilderness experience


Hematologic

Anemia

Coagulation disorder

Malignancy

Chemotherapy

Other conditions worsened by menses

Irritable bowel syndrome

Asthma

Postural tachycardia syndrome

Migraines


Combined oral contraceptives
The most commonly accepted and practices way to ensure menstrual suppression comes via continuous Combined oral contraceptives (COCPS)
-efficacy is 49%, 68% and 88% are 2, 6 and 12 cycles respectively
-monophasic OCPs are preferred 
-breakthrough bleeding (BTB) is the most common side effect and decreases with time
-lower estrogen levels in OCPs is associated with more BTB
-a hormone free break of 3-4 days is usually sufficient to manage BTB
-see two images below from the AAFP with guidelines on management of BTB

 

Additionally, menstrual suppression can occur using alternative contraceptive modes, including:
  • vaginal ring (skipping ring-free week)>> amenorrhea 89% at 6 months, BTB more common early and diminishes with time (NSAIDs may help, no studies on adding estrogen)
  • contraceptive patch (skipping patch-free week), not as well studied, no long term data, higher estrogen exposure, similar issues with BTB
  • hormonal IUD (Mirena, Liletta)>> amenorrhea 50% at 1 year, 60% at 5 years; lower dose IUD not effective at attaining amenorrhea, can uses NSAID/estrogen or OCPs for BTB
    • depo provera injections>> amenorrhea 50-75% at 1 year, increases with prolonged use; concerns about decreased bone density over time, also weight gain/mood changes. For BTB: NSAID, estrogen, cOCPs, decreasing injection interval (e.g. 2 months)
  • etonogestrel implant>> 22% amenorrhea at 1 year, improved with prolonged use, irregular BTB is common
Aside from using contraceptive methods to induce menstrual suppression, other medications can be used, including:
  • norethindrone acetate 5mg daily, not approved for contraception>> 76% amenorrhea at 2 years, can titrate up to 15mg daily (for BTB), different than norethindrone mini-pill (0.35)
  • testosterone therapy for trans and gender diverse patients >> testosterone therapy usually suppresses by 3-6 months, transmen generally prefer to avoid estrogen  (because of desire for masculinization)
  • GnRH agonists (puberty blockers), fast onset 4-6 weeks, high efficacy 96%, no increased prothrombotic use (often used in oncologic patients)
  • Danazol
Menstrual suppression considerations for people with disabilities:
  • can they swallow pills?
  • can they tolerate invasive procedure?
  • caution: bone density, weight gain, VTE risk in pts with decrease mobility at baseline
  • scheduled withdrawal bleeding may be preferred over random BTB
Don't forget this chart:

Childhood Immunization (Bernard-Pearl, 4/9/2025)

  A recording of this presentation is available HERE.  


Please check back for a summary soon!

Primary Care for Recent Immigrants (Kasten-Arias 4/2025)

A recording of this presentation is available HERE (check back for live link). *** Many thanks to Dr. Cassandra Kasten-Arias, who gave our f...